UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 15, 2020

Clinigence Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware   000-53862   11-3363609

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

55 Ivan Allen Jr. Blvd. NW, #875

Atlanta, Georgia

30308
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (678) 607-6393

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 par value   CLNH   OTCMKTS

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

  1  

 

 

Item 8.01 Other Events.

 

Due to the outbreak of coronavirus disease in 2019 (COVID-19), Clinigence Holdings, Inc, (the “Company”) is filing this current report on Form 8-K to avail itself of an extension to file its quarterly report on Form 10-Q for the period ended March 31, 2020, originally due on May 15, 2020 (the “Quarterly Report”), because additional time is required by Registrant’s management and auditors to prepare certain financial information to be included in such report.

 

The Company evaluated its ongoing effort to prepare and file its Quarterly Report and is unable to do so because of the impact of COVID-19, which, among other things, due to travel limitations and the requirements of “social distancing,” has adversely impacted and continues to adversely impact the ability of the individuals performing the required evaluation tasks to complete the filing on a timely basis.

 

Certain Company officers and management as well as professional staff and consultants are unable to conduct work required to prepare our financial report for the period ended March 31, 2020. As a result, the Company expects to be unable to compile and review certain information required in order to permit the Company to file a timely and accurate quarterly report on Form 10-Q for the period ended March 31, 2020 by the prescribed date without unreasonable effort or expense due to circumstances related to COVID-19.

 

Accordingly, as and to the extent the Company is unable to file the Quarterly Report on the due date, we are relying upon the order (the “Order”) issued by the Securities and Exchange Commission (the “SEC”) on March 4, 2020 pursuant to Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), extending the time (the “Extended Extension Period”) in which certain reports required to be filed pursuant to the Exchange Act are filed, and we are furnishing this Form 8-K as required pursuant to such order.

 

The Company is supplementing the risk factors previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2019 and its current Reports on Form 8-K, with the following risk factors:

        

The occurrence of an uncontrollable event such as the COVID-19 pandemic may negatively affect our operations.

 

A pandemic typically results in social distancing, travel bans and quarantine, and this may limit access to our facilities, customers, management, support staff and professional advisors. These factors, in turn, may not only impact our operations, financial condition and demand for our goods and services but our overall ability to react timely to mitigate the impact of this event. Also, it may hamper our efforts to comply with our filing obligations with the Securities and Exchange Commission.

 

  2  

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    Clinigence Holdings, Inc.
     
Date: May 15, 2020   /s/ Elisa Luqman
    Elisa Luqman
    Chief Financial Officer

  3  

 

 

Clinigence (PK) (USOTC:CLNH)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Clinigence (PK) Charts.
Clinigence (PK) (USOTC:CLNH)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Clinigence (PK) Charts.